China Resources Shuanghe: Wholly-owned subsidiary Boshengtan dispersible tablets obtained drug registration certificate.

China Resources Shuanghe Announcement: Wholly-owned subsidiary China Resources Shuanghe Limin Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" for Bosentan Dispersible Tablet issued by the National Medical Products Administration. The indication of Bosentan Dispersible Tablet is pulmonary arterial hypertension: used to improve pulmonary vascular resistance in pediatric patients aged 3 years with idiopathic or congenital PAH; used in the treatment of adult patients with pulmonary arterial hypertension WHO functional class II-IV. Shuanghe Limin started the research and development of generic drugs of this drug in 2022, received the acceptance notification on June 20, 2024, and obtained approval for listing by the National Medical Products Administration on September 23, 2025. As of the announcement date, the company's total research and development investment in this drug amounted to RMB 8,435,900.